Alzheimer's disease (AD) is a progressive neurodegenerative disease that causes chronic cognitive dysfunction. Most of the AD cases are late onset, and the apolipoprotein E () isoform is a key genetic risk factor. The gene has 3 key alleles in humans including , , and . Among them, is the most potent genetic risk factor for late-onset AD (LOAD), while has a defensive effect. Research data suggest that leads to the pathogenesis of AD through various processes such as accelerated beta-amyloid aggregations that raised neurofibrillary tangle formation, cerebrovascular diseases, aggravated neuroinflammation, and synaptic loss. However, the precise mode of actions regarding in what way leads to AD pathology remains unclear. Since contributes to several pathological pathways of AD, targeting might serve as a promising strategy for the development of novel drugs to combat AD. In this review, we focus on the recent studies about -targeted therapeutic strategies that have been advanced in animal models and are being prepared for use in humans for the management of AD.